Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients

Oral Oncology

Volumn 49, Issue 2, 2013, Pages 182-185

  Jiménez, Begoña ^a   Trigo, José M ^a   Pajares, Bella I ^a   Sáez, Maria I ^a   Quero, Cristina ^a   Navarro, Victor ^a   Llácer, Casilda ^a   Medina, Laura ^a   Rueda, Antonio ^b   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

Head and neck cancer; Paclitaxel plus cetuximab; Recurrent metastatic; Retrospective; Second line treatment

Indexed keywords

CETUXIMAB; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; RECURRENCE;

EID: 84872311568     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.09.003     Document Type: Article

References (22)

1. B.W. Stewart, and P.E. Kleihues World cancer report 2003 International Agency for Research on Cancer Press Lyon, France
2. M.J. Hayat, N. Howlader, and M.E. Reichman Cancer statistics, trends, and multiple primary cancer analyses for the surveillance, epidemiology and SEER results (SEER) program Oncologist 12 1 2007 20 37
3. P.M. Specenier, and J.B. Vermorken Recurrent head and neck cancer: current treatment and future prospects Expert Rev Anticancer Ther 8 2008 375 391
4. J. Vermorken NEJM 2008
5. J. Vermorken JCO 25 2007 2171 2177
6. Baselga J Clin Oncol 23 2005 5568 5577
7. Herbst J Clin Oncol 23 2005 5578 5587)
8. R. Hitt, A. Irigoyen, and H. Cortes-Funes Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck Ann Oncol 23 4 2012 1016 1022 [Epub 2011 Aug 23]
9. X. Leon Clin Oncol 17 418 2005 424
10. X. Pivot, S. Wadler, and C. Kelly Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer Ann Oncol 12 2001 1595 1599
11. C. Porta, S. Brugnateli, and E. Patruno Single-agent vinorelbine (VRB) as second-line treatment for advanced or recurrent squamous-cell carcinoma of the head AND neck (SCCHN) [abstract] Proc Am Soc Clin Oncol 20 Part 2 2001 [Abstract # 253:197b]
12. V. Gebbia, R. Valenza, and N. Borsellino Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck ORL J Otorhinolaryngol Relat Spec 56 5 1994 279 282
13. A. Iop, G. Cartei, and A. Isaia Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil Ann Oncol 9 1998 225 227
14. P. Schoffsky, T. Weihkopf, and A. Ganser Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel Anticancer Res 18 1998 4751 4756
15. G. Numico, and M. Merlano Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer Ann Oncol 13 2 2002 331 333
16. S. Zenda, Y. Onozawa, and N. Boku Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) Jpn J Clin Oncol 37 7 2007 477 481
17. M. Tahara, H. Minami, and Y. Hasegawa Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer Cancer Chemother Pharmacol 2010 [Epub ahead of print]
18. M.K. Knoedler, T. Gauler, and A. Matzdorff Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic platinum-pretreated SCCHN J Clin Oncol 27 15s 2009 [suppl; abstr 6048]
19. E. Massa, M. Dessi, and G. Gaspardini Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens Oral Oncol 46 2010 818 821
20. Hitt A, JCO. ASCO annual meeting proceedings (postmeeting edition), vol. 25. No. 18S (June 20 supplement); 2007.
21. K. Inoue, J. Slaton, and P. Perrotte Placlitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma Clin Cancer Res 11 2005 795 805
22. Danya Gholam, Amaleb Chebib, and Dominiqueb Hauteville Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer Anti-Cancer Drug 18 7 2007 835 837